165 related articles for article (PubMed ID: 32468256)
1. High resolution melting profiles (HRMPs) obtained by magnetic induction cycler (MIC) have been used to monitor the BRCA2 status highlighted by next generation tumor sequencing (NGTS): a combined approach in a diagnostic environment.
Mazzuccato G; De Bonis M; Carboni V; Marchetti C; Urbani A; Scambia G; Capoluongo E; Fagotti A; Minucci A
Mol Biol Rep; 2020 Jun; 47(6):4897-4903. PubMed ID: 32468256
[TBL] [Abstract][Full Text] [Related]
2. BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing.
Mafficini A; Simbolo M; Parisi A; Rusev B; Luchini C; Cataldo I; Piazzola E; Sperandio N; Turri G; Franchi M; Tortora G; Bovo C; Lawlor RT; Scarpa A
Oncotarget; 2016 Jan; 7(2):1076-83. PubMed ID: 26745875
[TBL] [Abstract][Full Text] [Related]
3. Performance of multiplicom's BRCA MASTR Dx kit on the detection of BRCA1 and BRCA2 mutations in fresh frozen ovarian and breast tumor samples.
Badoer C; Garrec C; Goossens D; Ellison G; Mills J; Dzial M; El Housni H; Berwouts S; Concolino P; Guibert-Le Guevellou V; Delnatte C; Del Favero J; Capoluongo E; Bézieau S
Oncotarget; 2016 Dec; 7(49):81357-81366. PubMed ID: 27793035
[TBL] [Abstract][Full Text] [Related]
4. Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples.
Zakrzewski F; Gieldon L; Rump A; Seifert M; Grützmann K; Krüger A; Loos S; Zeugner S; Hackmann K; Porrmann J; Wagner J; Kast K; Wimberger P; Baretton G; Schröck E; Aust D; Klink B
BMC Cancer; 2019 Apr; 19(1):396. PubMed ID: 31029168
[TBL] [Abstract][Full Text] [Related]
5. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer.
Chao A; Chang TC; Lapke N; Jung SM; Chi P; Chen CH; Yang LY; Lin CT; Huang HJ; Chou HH; Liou JD; Chen SJ; Wang TH; Lai CH
Oncotarget; 2016 Dec; 7(51):85529-85541. PubMed ID: 27907908
[TBL] [Abstract][Full Text] [Related]
7. BRCA1/2 somatic mutation detection in formalin-fixed paraffin embedded tissue by next-generation sequencing in Korean ovarian cancer patients.
Lee A; Kang J; Lee H; Lee YS; Choi YJ; Lee KH; Nistala GJ; Scafe CR; Choi J; Yoo J; Han M D E; Kim Y; Kim M
Pathol Res Pract; 2019 Nov; 215(11):152595. PubMed ID: 31570282
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous detection of BRCA mutations and large genomic rearrangements in germline DNA and FFPE tumor samples.
Enyedi MZ; Jaksa G; Pintér L; Sükösd F; Gyuris Z; Hajdu A; Határvölgyi E; Priskin K; Haracska L
Oncotarget; 2016 Sep; 7(38):61845-61859. PubMed ID: 27533253
[TBL] [Abstract][Full Text] [Related]
9. A novel BRCA1 duplication and new insights on the spectrum and frequency of germline large genomic rearrangements in BRCA1/BRCA2.
Sahin I; Saat H
Mol Biol Rep; 2021 Jun; 48(6):5057-5062. PubMed ID: 34146199
[TBL] [Abstract][Full Text] [Related]
10. Detection of somatic BRCA1/2 mutations in ovarian cancer - next-generation sequencing analysis of 100 cases.
Koczkowska M; Zuk M; Gorczynski A; Ratajska M; Lewandowska M; Biernat W; Limon J; Wasag B
Cancer Med; 2016 Jul; 5(7):1640-6. PubMed ID: 27167707
[TBL] [Abstract][Full Text] [Related]
11. Validation of multi-gene panel next-generation sequencing for the detection of BRCA mutation in formalin-fixed, paraffin-embedded epithelial ovarian cancer tissues.
Kim ET; Jeong HE; Yoon HJ; Kim KH; Suh DS
Taiwan J Obstet Gynecol; 2023 Jan; 62(1):66-70. PubMed ID: 36720553
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the pathogenic variants of BRCA1 and BRCA2 using next-generation sequencing in women with familial breast cancer: a case-control study.
Zayas-Villanueva OA; Campos-Acevedo LD; Lugo-Trampe JJ; Hernández-Barajas D; González-Guerrero JF; Noriega-Iriondo MF; Ramírez-Sánchez IA; Martínez-de-Villarreal LE
BMC Cancer; 2019 Jul; 19(1):722. PubMed ID: 31331294
[TBL] [Abstract][Full Text] [Related]
13. Diverse
Weigelt B; Comino-Méndez I; de Bruijn I; Tian L; Meisel JL; García-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY; Lim RS; Selenica P; Piscuoglio S; Aghajanian C; Norton L; Murali R; Hyman DM; Borsu L; Arcila ME; Konner J; Reis-Filho JS; Greenberg RA; Robson ME; Turner NC
Clin Cancer Res; 2017 Nov; 23(21):6708-6720. PubMed ID: 28765325
[No Abstract] [Full Text] [Related]
14. Detection of genomic variations in BRCA1 and BRCA2 genes by long-range PCR and next-generation sequencing.
Hernan I; Borràs E; de Sousa Dias M; Gamundi MJ; Mañé B; Llort G; Agúndez JA; Blanca M; Carballo M
J Mol Diagn; 2012; 14(3):286-93. PubMed ID: 22426013
[TBL] [Abstract][Full Text] [Related]
15. Cytology material is equivalent to tumor tissue in determining mutations of BRCA 1/2 genes in patients with tubo-ovarian high grade serous carcinoma.
Gornjec A; Novakovic S; Stegel V; Hocevar M; Pohar Marinsek Z; Gazic B; Krajc M; Skof E
BMC Cancer; 2019 Apr; 19(1):296. PubMed ID: 30940100
[TBL] [Abstract][Full Text] [Related]
16. [Testing of mutations in BRCA1 and BRCA2 genes in tumor tissues - possibilities and limitations].
Vošmiková H; Ryška A; Sieglová K; Laco J
Cesk Patol; 2016; 52(4):210-214. PubMed ID: 27869447
[TBL] [Abstract][Full Text] [Related]
17. Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas.
Weren RD; Mensenkamp AR; Simons M; Eijkelenboom A; Sie AS; Ouchene H; van Asseldonk M; Gomez-Garcia EB; Blok MJ; de Hullu JA; Nelen MR; Hoischen A; Bulten J; Tops BB; Hoogerbrugge N; Ligtenberg MJ
Hum Mutat; 2017 Feb; 38(2):226-235. PubMed ID: 27767231
[TBL] [Abstract][Full Text] [Related]
18. BRCA1 and BRCA2 Germline Mutation Screening in Western Algeria using High Resolution Melting Analysis (HRM).
Boulenouar ACS; Coulet F; Bendiab FMT; Boudinar FZ; Senhadji R
Gulf J Oncolog; 2018 May; 1(27):31-37. PubMed ID: 30145549
[TBL] [Abstract][Full Text] [Related]
19. [BRCA diagnostics of ovarian cancer : Molecular tumor testing since the introduction of PARP inhibitor therapy].
Löser H; Heydt C; Büttner R; Markiefka B
Pathologe; 2017 Mar; 38(2):117-126. PubMed ID: 28258387
[TBL] [Abstract][Full Text] [Related]
20. The landscape of BRCA1 and BRCA2 large rearrangements in an international cohort of over 20 000 ovarian tumors identified using next-generation sequencing.
Jones MA; Timms KM; Hatcher S; Cogan ES; Comeaux MS; Perry M; Morris B; Swedlund B; Elks CE; Lao-Sirieix P; Dearden S; Egile C; Brown JS; Harrington EA; Hodgson D; Stern M; Slavin TP; Mancini-DiNardo D
Genes Chromosomes Cancer; 2023 Oct; 62(10):589-596. PubMed ID: 37222498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]